Evidence map›Paper›PMID 39180266›Full record

ArticleAdvanced healthcare materials2024

Novel Nano Drug-Loaded Hydrogel Coatings for the Prevention and Treatment of CAUTI.

Jibin Wu, Jianling Yan, Sijia Xu, Xuan Zou, Yinghua Xu, Xiaobao Jin, Xuemei Lu, Shuiqing Gui

Abstract read
In one paragraph

Article in Advanced healthcare materials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jibin WuIntensive Care Unit, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen, 518031, P. R. China.
Jianling YanIntensive Care Unit, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen, 518031, P. R. China.
Sijia XuIntensive Care Unit, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen, 518031, P. R. China.
Xuan ZouShenzhen Center for Disease Control and Prevention, Shenzhen, 518055, P. R. China.
Yinghua XuKey Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, Beijing, 102629, P. R. China.
Xiaobao JinGuangdong Provincial Key Laboratory of Pharmaceutical Bioactive Substances, Institute of Pharmaceutical Bioactive Substances, School of Basic Medical Sciences, Guangdong Pharmaceutical University, Guangzhou, 510006, P. R. China.
Xuemei LuShenzhen Center for Disease Control and Prevention, Shenzhen, 518055, P. R. China.ORCID 0000-0002-0571-1472
Shuiqing GuiIntensive Care Unit, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen, 518031, P. R. China.

Funding

Basic and Applied Basic Research Foundation of Guangdong Province 2021A1515220119National Natural Science Foundation of China 32070509National Natural Science Foundation of China 82372161Sanming Project of Medicine in Shenzen Municipality SZSM202011008Sanming Project of Medicine in Shenzen Municipality SZSM202211016Shenzhen Fund for Guangdong Provincical High level Clinical Key Specialties SZGSP006Shenzhen Key Medical Discipline Construction Fund SZXK066Shenzhen Science and Technology Innovation Program JCYJ20220530150412027
6 · The paper itself

Abstract

Catheter-associated urinary tract infection (CAUTI) is a prevalent type of hospital-acquired infection, affecting approximately 15% to 25% of patients with urinary catheters. Long-term use of the catheter can lead to colonization of microorganisms and biofilm formation, and may develop into bacterial CAUTI. However, the frequent replacement of catheters in clinical settings can result in tissue damage, inflammation, ulceration, and additional complications, causing discomfort and pain for patients. In light of these challenges, a novel nanodrug-supported hydrogel coating called NP-AM/FK@OMV-P/H has been developed in this study. Through in vitro experiments, it is confirmed that OMV nano-loaded liquid gel coating has an effective reaction against E.coli HAase and releases antibacterial drugs. This coating has also demonstrated strong inhibition of E.coli and has shown the ability to inhibit the formation of bacterial biofilm. These findings highlight the potential of the OMV nanoparticle gel coating in preventing and treating bacterial infections. Notably, NP-AM/FK@OMV-P/H has exhibited greater efficacy against multidrug-resistant E.coli associated with UTIs compared to coatings containing single antimicrobial peptides or antibiotics. Additionally, it has demonstrated good biosecurity. In conclusion, the NP-AM/FK@OMV-P/H coating holds great potential in providing benefits to patients with CAUTI.

Indexed as

Anti-Bacterial AgentsBiofilmsEscherichia coliHydrogelsUrinary Tract InfectionsAnimalsCatheter-Related InfectionsCoated Materials, BiocompatibleHumansMicrobial Sensitivity TestsNanoparticlesUrinary CathetersAnti-Bacterial AgentsCoated Materials, BiocompatibleHydrogelsantibacterial & anti‐biofilmCAUTIhyaluronidase responsenano drug‐loaded hydrogel coatingOMV

Identifiers

PMID39180266
PMCPMC11616261

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.